Pharmaceutical News

RSS

Medicines do not degrade after being stored in space, shows study

The results of an opportunistic, pilot-scale study led by Virginia Wotring of the Center for Space Medicine and Department of Pharmacology at Baylor College of Medicine in the US suggest that medication degradation on the International Space Station (ISS) does not differ from what is typically seen on Earth.

11 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Perrigo receives FDA approval for generic version of KlorCon extended-release tablets

Perrigo Company plc today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration approval for the generic version of KlorCon extended-release tablets (600 mg and 750 mg), manufactured by Upsher-Smith Laboratories, Inc., and marketed by Sandoz Pharmaceuticals, Inc.

10 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

New vaccine appears to be more effective in reducing 'bad' LDL cholesterol

A new cholesterol-lowering vaccine leads to reductions in 'bad' LDL cholesterol in mice and macaques, according to research published in Vaccine. The authors of the study, from the University of New Mexico and the National Institutes of health in the United States, say the vaccine has the potential to be a more powerful treatment than statins alone.

10 Nov 2015

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).

10 Nov 2015

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Efforts to treat myotonic dystrophy type 1, the most common form of muscular dystrophy, are in their infancy. In a new study, researchers report they have added new capabilities to an experimental drug agent that previously defeated only one of DM1's many modes of action. Their retooled compounds interrupt the disease's pathology in three ways.

10 Nov 2015

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

10 Nov 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure.

10 Nov 2015

PAREXEL expands market access and clinical evidence services

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced expanded evidence-based services for biopharmaceutical products.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.

10 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics.

6 Nov 2015

MSU professor finds surprising results about drug use behaviors

Conducting an economic analysis of drug use is a particularly difficult endeavor, but for Michigan State University professor and economist Siddharth Chandra, it just meant taking a look at the history books.

6 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Pharmaceutical News

Medicines do not degrade after being stored in space, shows study

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Perrigo receives FDA approval for generic version of KlorCon extended-release tablets

New findings reveal association between colorectal cancer and melanoma drug treatment

New vaccine appears to be more effective in reducing 'bad' LDL cholesterol

L-DOPA drug may delay or prevent age-related macular degeneration

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

PAREXEL expands market access and clinical evidence services

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

AACR rapid and dramatic responses in TRK fusion patients

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

MSU professor finds surprising results about drug use behaviors

Genvoya approved as complete regimen for HIV treatment

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News